S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

NASDAQ:CRTX - Cortexyme Stock Price, Forecast & News

$72.51
+8.41 (+13.12 %)
(As of 02/17/2020 01:07 PM ET)
Today's Range
$63.61
Now: $72.51
$73.84
50-Day Range
$42.65
MA: $53.59
$72.51
52-Week Range
$19.35
Now: $72.51
$73.84
Volume232,252 shs
Average Volume138,934 shs
Market Capitalization$1.95 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:CRTX
CUSIP21924P10
Phone415-910-5717

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-12,480,000.00

Miscellaneous

Employees16
Market Cap$1.95 billion
Next Earnings Date2/18/2020 (Estimated)
OptionableNot Optionable

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.


Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) posted its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.00. View Cortexyme's Earnings History.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Cortexyme.

What price target have analysts set for CRTX?

3 brokerages have issued 12-month price targets for Cortexyme's shares. Their forecasts range from $14.00 to $53.00. On average, they expect Cortexyme's share price to reach $34.25 in the next twelve months. This suggests that the stock has a possible downside of 52.8%. View Analyst Price Targets for Cortexyme.

What is the consensus analysts' recommendation for Cortexyme?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cortexyme.

Has Cortexyme been receiving favorable news coverage?

Media stories about CRTX stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cortexyme earned a news impact score of 1.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Cortexyme.

Are investors shorting Cortexyme?

Cortexyme saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,410,000 shares, a decrease of 9.0% from the January 15th total of 1,550,000 shares. Based on an average trading volume of 180,500 shares, the short-interest ratio is presently 7.8 days. Approximately 15.6% of the company's stock are sold short. View Cortexyme's Current Options Chain.

Who are some of Cortexyme's key competitors?

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include Alibaba Group (BABA), Honeywell International (HON), Thermo Fisher Scientific (TMO), Home Depot (HD), Cisco Systems (CSCO), CVS Health (CVS), Verizon Communications (VZ), Procter & Gamble (PG), Johnson & Johnson (JNJ) and Raytheon (RTN).

Who are Cortexyme's key executives?

Cortexyme's management team includes the folowing people:
  • Ms. Casey C. Lynch, Co-Founder, Chairman, Pres & CEO (Age 45)
  • Mr. Stephen S. Dominy, Co-Founder, Chief Scientific Officer & Director (Age 63)
  • Ms. Kristen Gafric, Co-Founder, Sr. VP of Legal & Admin. and Sec. (Age 43)
  • Mr. Christopher P. Lowe, CFO & Treasurer (Age 48)
  • Dr. Michael J. Detke, Chief Medical Officer (Age 52)

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (0.66%), Marshall Wace North America L.P. (0.39%), Charles Schwab Investment Management Inc. (0.16%), Bank of New York Mellon Corp (0.14%), UBS Group AG (0.10%) and Barclays PLC (0.05%). Company insiders that own Cortexyme stock include Epiq Capital Group, Llc and Pfizer Inc. View Institutional Ownership Trends for Cortexyme.

Which major investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP and Goldman Sachs Group Inc.. View Insider Buying and Selling for Cortexyme.

Which major investors are buying Cortexyme stock?

CRTX stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Marshall Wace North America L.P., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Rhumbline Advisers, Virtus ETF Advisers LLC, Barclays PLC and UBS Group AG. Company insiders that have bought Cortexyme stock in the last two years include Epiq Capital Group, Llc and Pfizer Inc. View Insider Buying and Selling for Cortexyme.

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $72.51.

How big of a company is Cortexyme?

Cortexyme has a market capitalization of $1.95 billion. Cortexyme employs 16 workers across the globe.View Additional Information About Cortexyme.

What is Cortexyme's official website?

The official website for Cortexyme is http://www.cortexyme.com/.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 415-910-5717 or via email at [email protected]


MarketBeat Community Rating for Cortexyme (NASDAQ CRTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  133 (Thanks for Voting!)
Underperform Votes:  109 (Thanks for Voting!)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about Cortexyme and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel